Titre :

Ibrutinib Associated with Rituximab-Platinum Salt-Based Immunochemotherapy in B-Cell Lymphomas: Results of a Phase 1b-II Study of the LYSA Group.

Auteur(s) :

Bonnet, C. [Auteur]
Centre Hospitalier Universitaire de Liège [CHU-Liège]
Dupuis, J. [Auteur]
Tilly, H. [Auteur]
Lamy, T. [Auteur]
Centre Hospitalier Universitaire de Rennes [CHU Rennes] = Rennes University Hospital [Pontchaillou]
Fruchart, C. [Auteur]
Le Gouill, S. [Auteur]
Thieblemont, C. [Auteur]
Morschhauser, Franck [Auteur]
Groupe de Recherche sur les formes Injectables et les Technologies Associées (GRITA) - ULR 7365
Casasnovas, O. [Auteur]
Bouabdallah, K. [Auteur]
Ghesquieres, H. [Auteur]
Service d’Hématologie [Centre Hospitalier Lyon Sud - HCL]
Van Den Neste, E. [Auteur]
André, M. [Auteur]
Cartron, G. [Auteur]
CHU Montpellier = Montpellier University Hospital
Salles, G. [Auteur]

Titre de la revue :

Cancers

Nom court de la revue :

Cancers

Numéro :

14

Pagination :

1761

Éditeur :

MDPI

Date de publication :

2022-03-30

ISSN :

2072-6694

Mot(s)-clé(s) :

relapsed
refractory non-Hodgkin B-cell lymphoma
ibrutinib
R-DHAP
R-DHAOx
safety

Discipline(s) HAL :

Sciences du Vivant [q-bio]

Résumé en anglais : [en]

In the post-rituximab era, patients with relapsed/refractory non-Hodgkin B-cell lymphoma (R/R B-NHL) responding to a platinum salt-based salvage regimen can potentially be cured after intensification followed by autologous ...
Lire la suite >In the post-rituximab era, patients with relapsed/refractory non-Hodgkin B-cell lymphoma (R/R B-NHL) responding to a platinum salt-based salvage regimen can potentially be cured after intensification followed by autologous stem cell transplantation, with the quality of the response to salvage predicting survival. The Bruton tyrosine kinase inhibitor ibrutinib, given as monotherapy or combined with other molecules, has proven effective in numerous B-cell lymphomas. To evaluate the safety of the combination of ibrutinib, rituximab, dexamethasone, and cytarabine with either cisplatin (R-DHAP) or oxaliplatin (R-DHAOx), we conducted a multicenter Phase 1b-II study in transplant-eligible R/R B-NHL patients, with ibrutinib given using a 3-by-3 dose-escalation design. The combination of R-DHAP and ibrutinib (given from Day 1 to Day 21 of each cycle) was associated with dose-limiting hematological, infectious, and renal toxicities, while we were unable to reach a dose to recommend for Phase II. R-DHAOx could only be combined with a daily dosage of 280 mg ibrutinib when administered continuously. R-DHAP combined with intermittent ibrutinib administration (from Day 5 to Day 18) was found to be highly toxic. On the other hand, when this administration schedule was combined with R-DHAOx, ibrutinib dosing could be increased up to 560 mg but with relevant toxicities. Despite a strong rationale for combining ibrutinib and R-DHAP/R-DHAOx, as both target lymphoma B-cells by different mechanisms, this approach was limited by significant toxicities.Lire moins >

Langue :

Anglais

Audience :

Internationale

Vulgarisation :

Non

Établissement(s) :

Université de Lille
CHU Lille

Collections :

• Groupe de Recherche sur les formes Injectables et les Technologies Associées (GRITA) - ULR 7365

Date de dépôt :

2023-05-25T02:42:37Z
2023-07-12T08:52:45Z